Nyxoah

Company Overview

Snapshot

Founded in January 2008 by Robert Taub, Nyxoah operates with 51–200 employees. The company has raised a total of $270.7 million across 10 funding rounds from 9 investors. In May 2024, Nyxoah announced the pricing of an offering on NASDAQ.

Business overview

Nyxoah is a medical device company specializing in the development and commercialization of hypoglossal nerve stimulation therapy for treating obstructive sleep apnea (OSA). Its core technology is a battery-free, leadless, minimally invasive neurostimulator designed to deliver bilateral hypoglossal nerve stimulation. This therapy targets patients with moderate to severe OSA who have not responded to conventional positive airway pressure therapy. The company's product, Genio, is implanted in the chin area and powered by a miniature external battery to stimulate the tongue nerve. Nyxoah operates within the Health Tech & Life Sciences sector, focusing on medical devices, neuro-stimulation, and therapeutic treatments for sleep disorders and chronic patients.

Strategic signal

In October 2024, Nyxoah secured $27 million through an At-the-Market offering, signaling a strategic focus on bolstering its presence in the U.S. market. This capital infusion is crucial for accelerating commercialization efforts and expanding access to its Genio system, demonstrating investor confidence in the company's growth trajectory and market penetration strategy.

Company Intelligence Q&A

What is Nyxoah's primary focus?

Nyxoah is focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA).

When did Nyxoah go public on Euronext?

Nyxoah launched its Initial Public Offering on Euronext Brussels in September 2020.

What was a significant financial event for Nyxoah in October 2024?

In October 2024, Nyxoah raised $27 million through an At-the-Market offering to boost its U.S. presence.

When did Nyxoah announce its first U.S. commercial patients implanted with the Genio System?

Nyxoah announced the first U.S. commercial patients implanted with its Genio System in October 2025.

What was a key partnership announced by Nyxoah in September 2023?

In September 2023, Nyxoah announced a partnership with ResMed in Germany to expand the commercialization of its Genio system for obstructive sleep apnea patients.